Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome
Perimenopausal syndrome (PMS) is a common condition affecting women during the transition to menopause, often causing hot flashes, sweating, insomnia, anxiety, depression, fatigue, and reduced quality of life. Current hormone replacement therapy can improve symptoms, but long-term use may increase the risk of breast cancer and cardiovascular complications. Therefore, safer and more effective alternative treatments are needed.
Jinfeng Pill is a traditional Chinese medicine patented drug that has been widely used in gynecological disorders. Previous studies suggest that it may help regulate hormone balance, improve ovarian function, and reduce inflammation. Recent research has also shown that intestinal bacteria ("gut microbiota") may influence estrogen metabolism through the "gut microbiota-estrogen axis," which could play an important role in perimenopausal symptoms.
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness and safety of Jinfeng Pill in women with perimenopausal syndrome. Eligible participants will be randomly assigned to receive either Jinfeng Pill or a placebo for 12 weeks. Researchers will assess changes in menopausal symptoms, mood, sleep, and quality of life using standardized questionnaires and laboratory tests.
In addition, the study will explore how Jinfeng Pill may regulate gut microbiota, β-glucuronidase (β-GUS) activity, short-chain fatty acids (SCFAs), inflammatory factors, and estrogen-related indicators. The findings may provide new evidence for the clinical use of traditional Chinese medicine in the treatment of perimenopausal syndrome and help clarify its underlying biological mechanisms.
研究概览
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Xiaohu Xu
- 电话号码:+8613006111902
- 邮箱:hermanxu@163.com
学习地点
-
-
Hubei
-
Wuhan、Hubei、中国、430000
- 招聘中
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
接触:
- Xiao Wu Dr
- 电话号码:+8613237124563
- 邮箱:wuxiao0609@163.com
-
Wuhan、Hubei、中国、430000
- 招聘中
- Hubei Maternal and Child Health Hospital,Tongji Medical College of Huazhong University of Science and Technology
-
接触:
- Man Tian
- 电话号码:+8615007163910
- 邮箱:396617040@qq.com
-
Wuhan、Hubei、中国、430000
- 招聘中
- Wuhan Children's Hospital (Wuhan Maternal and Child Health Hospital),Tongji Medical College of Huazhong University of Science and Technology
-
接触:
- Lishan Zhou
- 电话号码:+8618086029059
- 邮箱:sophiachou0913@126.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female patients aged 45-55 years;
- Menstrual disorders (prolonged menstrual cycle or hypomenorrhea) lasting for more than 3 months, or amenorrhea for 2-12 months;
- Presence of vasomotor symptoms (hot flashes, sweating), somatic symptoms (insomnia, fatigue, headache, paresthesia), psychological symptoms (anxiety, depression), or urogenital symptoms (dyspareunia, vaginal dryness, urinary tract infection);
- Serum follicle-stimulating hormone (FSH) > 10 IU/L, or decreased estradiol (E2) levels;
- No use of HRT or other medications for perimenopausal symptoms in the past 2 months;
- Intact uterus and bilateral adnexa, not surgically removed;
- Voluntary participation and signing of informed consent;
- Modified Kupperman Index (KI score) ≥ 6, indicating mild or above symptoms.
Exclusion Criteria:
- Does not meet the inclusion criteria listed above;
- Ovarian malignancy, ovarian or hysterectomy, premature ovarian failure, uterine fibroids ≥2 cm, severe breast hyperplasia;
- Acute gynecological infectious diseases or other acute infectious diseases;
- Severe liver or kidney dysfunction, or other serious systemic diseases;
- Use of hormonal drugs or traditional Chinese medicine for treatment in the past 2 months;
- Participation in other clinical trials;
- Patients who did not adhere to the treatment protocol or withdrew from the trial;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo group
Placebo |
Placebo |
|
实验性的:Jinfeng Pill group
Jinfeng Pill |
Jinfeng Pill |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The modified Kupperman Index (KI)
大体时间:Week -1, Week 0, Week 4, Week 8, Week 12, Week 16
|
The total score of KI is 63. It includes 13 items related to peri-menopausal syndrome, and the severity score of each item ranges from 0 to 3. There were different basic score in each item: hot flashes and sweating = 4; Paresthesia, sleep disorders, nervousness, sexual complaints, urinary tract infection = 2; the other items = 1. Item score = basic score × severity score. Classification standard of disease condition: mild: symptom score <13; moderate: symptom score 14-26; severe: symptom score >27 points. |
Week -1, Week 0, Week 4, Week 8, Week 12, Week 16
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hot flash scale (HFs)
大体时间:Week -1, Week 0, Week 4, Week 8, Week 12, Week 16
|
The severity of hot flash was evaluated using visual analog scale (0-10).The higher the value, the more severe the symptoms. |
Week -1, Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Menopause-specific quality of life scale (MENQOL)
大体时间:Week 0, Week 12, Week 16
|
MENQOL contains 27 questions related to vasomotor symptoms, psychological symptoms, physiological symptoms, and sexual life. A lower MENQOL score indicates PMPS has a less influence on life quality. |
Week 0, Week 12, Week 16
|
|
Hamilton depressive scale (HAMD)
大体时间:Week 0, Week 12, Week 16
|
The items of HAMD are scored on a 5-level scale with 0-4 points, a few items is a 3-level scale with 0-2 points. A higher score indicates the more severe depression. |
Week 0, Week 12, Week 16
|
|
Hamilton anxiety scale (HAMA)
大体时间:Week 0, Week 12, Week 16
|
HAMA contains 14 items related to a number of anxiety symptoms. Each of items is scored on a 5-level scale with 0-4 points. A higher score indicates the more severe anxiety. |
Week 0, Week 12, Week 16
|
|
Vaginal Health Index (VHI)
大体时间:Week 0, Week 12
|
The VHIS (Vaginal Health Index) comprises five assessment dimensions, each scored from 1 to 5 points, for a total of 25 points. A higher total score indicates better vaginal health, while a total score below 15 points suggests vaginal atrophy. |
Week 0, Week 12
|
|
TCM Syndrome Score Scale
大体时间:Week 0, Week 12
|
Symptom severity will be graded according to the Guiding Principles for Clinical Research of New Chinese Medicines for eight TCM-specific symptom domains (hot flushes and sweating, menstrual irregularity, irritability, dizziness and headache, lumbar and knee soreness, insomnia with vivid dreaming, hypochondriac pain with bitter taste, and vaginal dryness), each rated 0-3 (absent/mild/moderate/severe). The total score is 24 points, with higher scores indicating more severe symptoms. |
Week 0, Week 12
|
|
Serum levels of sex hormones (E2, FSH, LH) and estrogen metabolites (2-OHE1,16α-OHE1)
大体时间:Week 0, Week 12
|
Serum E2, FSH, and LH will be quantified by enzyme-linked immunosorbent assay (ELISA). Estrogen metabolites - 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16α-OHE1) - will be determined by liquid chromatography-mass spectrometry (LC-MS). |
Week 0, Week 12
|
|
Serum inflammatory factors (IL-6, TNF-α)
大体时间:Week 0, Week 12
|
Serum concentrations of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) will be measured by ELISA |
Week 0, Week 12
|
|
Intestinal microbiota β-GUS enzyme activity
大体时间:Week 0, Week 12
|
β-GUS activity will be determined spectrophotometrically via the enzymatic hydrolysis of p-nitrophenyl-β-D-glucuronide (pNPG) to p-nitrophenol (pNP), quantified by absorbance at 405 nm. |
Week 0, Week 12
|
|
Short-Chain Fatty Acids (SCFAs)
大体时间:Week 0, Week 12
|
Faecal concentrations of acetic acid, propionic acid, and butyric acid will be determined by gas chromatography. |
Week 0, Week 12
|
|
Gut Microbiota Analysis
大体时间:Week 0, Week 12
|
Faecal samples will be collected at baseline and week 12. Participants will provide ≥5 mg of stool into a sterile collection tube, which will be immediately snap-frozen in liquid nitrogen and stored at -80°C pending analysis. Bacterial genomic DNA will be extracted using the QIAamp Swab DNA Kit (QIAGEN). The V3-V4 hypervariable regions of the 16S rRNA gene will be amplified by PCR and sequenced on the Illumina NextSeq 2000 platform. |
Week 0, Week 12
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- TJ-IRB202512083
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Protecting participant privacy and data security.To consider potential data needs, please contact authorized researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.